

ASX / Media Release

Shareholder Update

*Further process update to shareholders on proposal
to acquire remaining shares in APH by Strides Arcolab Limited*

12 November 2010, Melbourne: Ascent Pharmahealth Ltd (ASX:APH) through the Independent Board Committee (IBC), led by the Chairman Mr Warren Jenkins, would like to provide shareholders with the following update on discussions with Strides Arcolab Limited (**Strides**) in relation to its proposal regarding a possible scheme of arrangement under which Strides would acquire the remaining shares in APH at a price of \$0.35 cash per share.

Since the last shareholder update of 18 August, there has been no formal offer submitted by Strides to the IBC. Strides has recently confirmed its interest in proceeding on the basis as previously outlined to APH shareholders on 18 August 2010 and has advised it expects to complete financial due diligence with its financiers within the next 2 weeks.

Whilst the IBC is continuing its discussions with Strides, the IBC notes that there is currently no formal agreement in place with Strides and it should not be assumed that negotiations with Strides will result in a completed transaction. The IBC's willingness to progress the Strides proposal remains subject to conditions outlined in the shareholder update of 18 August 2010.

Given the passage of time since its initial approach, the IBC notes that if any transaction does eventuate it will not complete until the new calendar year. APH will continue to keep its shareholders informed and will make further announcements if any of the conditions to the proposal are satisfied, or if there are any other material developments with the proposed transaction.

Inquiries:

Andrew Burgess

Company Secretary
Ascent Pharmahealth Ltd
+61 3 8677 6660

About Ascent:

Ascent Pharmahealth Ltd (ASX:APH) sells over 400 products in eight countries. It is one of Australia's and Asia's fastest growing and most dynamic pharmaceutical businesses. Ascent registers, markets, distributes and sells generic pharmaceuticals, consumer skincare and over-the-counter medicines. Key subsidiaries are Ascent Pharmaceuticals, one of Australia's top 5 generic pharmaceutical companies and Drug Houses of Australia, Singapore's largest generic pharmaceutical company with products distributed across seven Asian countries. The company listed on the Australian Securities Exchange in June 2004.

For more information visit: www.ascentpharma.com.au.

Ascent Pharmahealth Limited

ABN 52 107 340 367

151-153 Clarendon Street, South Melbourne, Victoria 3205, Australia

Tel: +61 3 8677 6660 Fax: +61 3 8677 6666